In lung adenocarcinoma patients, ALYREF, together with NSUN2, promotes m5C modification of YAP (Yes-Associated Protein) mRNA in the 3’-UTR, thus increasing the stability of YAP mRNA and causing enhanced exosome secretion, tumor malignancy and drug resistance (91). This evidence concerns the gene ALYREF and lung adenocarcinoma.